Tandem Diabetes Care (TNDM) stock has drawn attention after recent trading left it at a last close of $17.17, prompting investors to reassess its performance over the past month and past 3 months.

At a share price of $17.17, Tandem Diabetes Care has seen a modest 30 day share price return of 5.73%. However, its year to date share price return is down 20.32%, and the 3 year total shareholder return is down 50.83%. This points to fading momentum despite a slightly positive 1 year total shareholder return of 1.96%.

If you are comparing Tandem Diabetes Care with other opportunities in medical technology, it may be worth scanning similar ideas across healthcare AI using the 41 healthcare AI stocks.

For Tandem Diabetes Care, the recent bounce after a weaker multi year run could hint at renewed confidence in the insulin pump business, or simply reflect a short term shift in sentiment. So how does the current valuation stack up?

Most Popular Narrative: 41.2% Undervalued

On the latest close at $17.17, the most followed narrative for Tandem Diabetes Care points to a fair value of $29.20. This puts the current price at a steep discount and focuses attention on long term earnings potential rather than recent share price swings.

Broader pharmacy channel expansion and acceleration of pharmacy based supply sales are expected to lower out of pocket costs, increase pump adoption rates, and shift more high margin recurring supply sales through premium priced channels, supporting future revenue growth, margin expansion, and improved earnings.

Want to see what underpins that confidence in Tandem Diabetes Care? The narrative leans on steady revenue growth, a turn to profitability, and a richer earnings multiple. Curious which assumptions really move that $29.20 fair value?

Result: Fair Value of $29.20 (UNDERVALUED)

However, Tandem Diabetes Care still faces real pressure from stronger competitors and flat renewal expectations, which could weigh on pump starts and recurring revenue assumptions.

Next Steps

Given the mix of caution and optimism around Tandem Diabetes Care, it makes sense to act promptly and review the underlying data yourself, then weigh up the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Tandem Diabetes Care?

If Tandem Diabetes Care has caught your attention, do not stop there, broaden your watchlist with other focused ideas that could suit different goals and risk levels.

• Spot potential upside early by scanning screener containing 20 high quality undiscovered gems before they show up on everyone else's radar.
• Strengthen your core holdings by filtering for companies in the solid balance sheet and fundamentals stocks screener (49 results) that prioritise financial resilience.
• Reduce portfolio stress by concentrating on 84 resilient stocks with low risk scores that may offer a smoother ride through market swings.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.